scPharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview

Scpharmaceuticals

05/08/2025 21:02

scPharmaceuticals Inc SCPH.OQ SCPH.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Burlington Massachusetts-based  company is expected to report a 91.4% increase in revenue to $15.413 million from $8.05 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for scPharmaceuticals Inc is for a loss of 30 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for scPharmaceuticals Inc is $12.00, about 54% above its last closing price of $5.52

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.32
-0.30
-0.37
Missed
-24.2
Dec. 31 2025
-0.44
-0.38
-0.35
Beat
7.5
Sep. 30 2024
-0.29
-0.30
-0.75
Missed
-153​
Jun. 30 2024
-0.42
-0.41
-0.44
Missed
-6.3
​​Mar. 31 2024
-0.44
-0.44
-0.36
Beat
17.6
Dec. 31 2023
-0.52
-0.42
-0.35
Beat
16.4​
Sep. 30 2023
-0.37
-0.36
-0.41
Missed
-12.4
Jun. 30 2023
-0.37
-0.37
-0.36
Beat
3.3

This summary was machine generated August 5 at 20:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)